Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 12.39%, which has investors questioning if this is right time ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms, Lexicon ...

Shares of LXRX opened at $0.42 on Friday. The firm has a fifty day simple moving average of $0.57 and a two-hundred day simple moving average of $0.96. The firm has a market cap of $103.15 million ...

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) climbed ~95% in the premarket trading on Friday after the Texas-based biotech announced an exclusive license agreement with Novo Nordisk (NVO ...

LXRX opened at $0.36 on Thursday. The firm has a market cap of $89.43 million, a P/E ratio of -0.48 and a beta of 1.04. The firm has a 50-day moving average of $0.64 and a 200 day moving average ...

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average target of $3.83, a high estimate of $6.00, and a low estimate of $1.00. This ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...